Natalizumab discontinuation and disease restart in pregnancy: a case series.
Acta Neurol Scand
; 131(5): 336-40, 2015 May.
Article
en En
| MEDLINE
| ID: mdl-25598313
ABSTRACT
BACKGROUND:
The humanized monoclonal alpha4-integrin antibody Natalizumab (NTZ) (Tysabri(©) , Biogen Idec, Cambridge, MA, USA) has shown to be effective in multiple sclerosis (MS) therapy; however, the interruption of the drug has been related to a disease restart. This risk has to be carefully considered in case of accidental or desired pregnancies. AIM OF THE STUDY To report the risk of disease restart in patients who interrupted NTZ because of pregnancy and discuss the implication of NTZ choice in female childbearing patients with MS.METHODS:
Clinical histories and MRI images of four pregnant women with MS who interrupted NTZ.RESULTS:
Despite pregnancy is usually related with disease stability, the cases presented here showed an abrupt increase of disability with high number of MRI lesions, some of them with a mass effect.CONCLUSIONS:
We recommend that female patients on childbearing age must be informed before starting NTZ treatment of the risk of a return of disease activity when the drug is discontinued. The risk occurs even during pregnancy a condition that is considered as protective for women with MS.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Complicaciones del Embarazo
/
Embarazo
/
Anticuerpos Monoclonales Humanizados
/
Esclerosis Múltiple
Límite:
Adult
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
Acta Neurol Scand
Año:
2015
Tipo del documento:
Article
País de afiliación:
Italia